Bring Vaccines to Market Faster

Wednesday, November 5th at 8:30 am ET

Innovation in Analytical Characterization Tools for Vaccine Development

In this keynote, Erica will highlight the diversity of vaccine modalities and why analytics are so important in the post-COVID pandemic era of rapid vaccine development. She will discuss the similar challenges faced across modalities and present a few case studies of recent interesting vaccine analytical technologies, including examples highlighting InDevR’s VaxArray approach to vaccine analytics.

This conference is organized by United Scientific Group (A 501(C) 3 Non-profit Organization).

Dr. Erica Dawson is Chief R&D Officer at InDevR, a Boulder, CO-based life science tools company founded in 2003 where she leads the R&D, Engineering, and Field Application Science teams. In this role that straddles product development and commercial activities, she guides the development and expansion of InDevR’s VaxArray technology portfolio and related IP as well as oversees the team of scientists providing customer support. With InDevR since 2006, Dr. Dawson has acted as program manager or PI on most of InDevR’s historical ~$45M in non-dilutive grants and contracts, including current or past funding from NIH/NIAID, the Bill & Melinda Gates Foundation, and NIIMBL. In addition, she led a $15M BARDA contract for the development of an influenza molecular diagnostic with clinical and pandemic preparedness applications which resulted in successful 510(k) clearance in April 2019. Dr. Dawson earned her B.S. in Chemistry from Hartwick College (summa cum laude), her Ph.D. in Analytical Chemistry from The University of North Carolina at Chapel Hill, and completed postdoctoral training in microarray-based molecular diagnostics at the University of Colorado at Boulder.

Discover the VaxArray Platform, your solution in multiplexed immunoassays designed to streamline vaccine development and analysis. This state-of-the-art system offers unparalleled precision and efficiency, empowering researchers to achieve faster, more reliable results in their efforts to advance public health.

• Multiplex 50+ Analytes in Triplicate – VaxArray multiplexed technology outpaces traditional single-plex methods like ELISA in speed and efficiency.
• Results in 1 Hour – Faster time to result compared to other technologies.
• Versatile Platform – analyze a wide range of vaccine-relevant samples, from antibodies and antigens to nucleic acids.